GlassScriptPhysician profile
James W Fulton
NPI 1346521887
$21,203.58
in general payments reported to CMS, 2019-2025
35 companies · $3,874 in 2025
The $3,874 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $2,811 · 2021: $2,039 · 2022: $2,891 · 2023: $4,212 · 2024: $4,547 · 2025: $3,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $1,143 · Consulting Fee: $785 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,591.59 |
| Travel and Lodging | $1,143.29 |
| Consulting Fee | $785.29 |
| Education | $113.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,677.03 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Genzyme Corporation | $3,011.58 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,238.04 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Glaxosmithkline, LLC. | $1,898.87 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Adare Pharmaceuticals, INC. | $1,515.31 | 2020 | |
| Csl Behring | $1,113.03 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Biocryst US Sales Co., LLC | $778.14 | 2021-2025 | Orladeyo |
| Genentech USA, INC. | $583.66 | 2020-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $547.20 | 2019-2025 | Dupixent |
| Amgen INC. | $519.46 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $466.72 | 2019-2025 | |
| Optinose US, INC. | $463.49 | 2019-2025 | |
| Grifols USA, LLC | $416.91 | 2020-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Pharming Healthcare, INC. | $327.28 | 2021-2025 | Ruconest, Joenja |
| Sanofi-Aventis U.S. LLC | $221.18 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $192.56 | 2023-2025 | |
| Qol Medical, LLC | $183.44 | 2019-2024 | Sucraid, Sucraid |
| Pfizer INC. | $147.46 | 2019-2025 | |
| Biomarin Pharmaceutical INC. | $135.36 | 2023 | |
| Kaleo, INC. | $117.72 | 2019-2024 | Auvi-Q |
| Octapharma USA, INC. | $98.18 | 2020-2024 | Cutaquig |
| Ars Pharmaceuticals Operations, INC. | $87.66 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $83.31 | 2020-2023 | Airduo Digihaler |
| Ionis Pharmaceuticals, INC. | $76.61 | 2025 | Dawnzera |
| Blueprint Medicines Corporation | $61.86 | 2023-2024 | Ayvakit |
| Cycle Pharmaceuticals INC | $46.37 | 2024-2025 | Sajazir |
| Aimmune Therapeutics, INC. | $44.85 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.62 | 2019-2021 | |
| Shire North American Group INC | $26.80 | 2019 | |
| Phadia US INC. | $21.66 | 2025 | Immunocap |
| Biocryst Pharmaceuticals, INC. | $21.52 | 2020 | |
| Galderma Laboratories, L.P. | $18.33 | 2025 | Nemluvio |
| Incyte Corporation | $17.45 | 2021 | |
| Adma Biomanufacturing LLC | $7.29 | 2025 | |
| Organon LLC | $3.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fulton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.